Combined immunotherapy targeting the immune checkpoint receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1), or CTLA-4 and the PD-1 ligand (PD-L1) exhibits superior anti-tumor responses compared with single-agent therapy. Here, we examined the molecular basis for this synergy. Using reconstitution assays with fluorescence readouts, we found that PD-L1 and the CTLA-4 ligand CD80 heterodimerize in cis but not trans. Quantitative biochemistry and cell biology assays revealed that PD-L1:CD80 cis-heterodimerization inhibited both PD-L1:PD-1 and CD80:CTLA-4 interactions through distinct mechanisms but preserved the ability of CD80 to activate the T cell co-stimulatory receptor CD28. Furthermore, P...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
CTLA-4 and PD-1 are key immune checkpoint receptors that are targeted in the treatment of cancer. A ...
International audienceCD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal ...
Tumor cells are capable of limiting antitumor CD8+ T cell responses through their cell surface expre...
CD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal positive and negative ...
Subsets of human tumors are infiltrated with tumor antigen-specific CD8+ T cells (TIL), yet despite ...
Costimulatory molecules function to stimulate or inhibit T cell activation. A balance between activa...
Immunotherapy is a promising approach for the treatment of primary and metastatic cancer because of ...
Tumor cells can inhibit immune responses against their survival by activating inhibitory immune chec...
Many cancers are termed immunoevasive due to expression of immunomodulatory ligands. Programmed deat...
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early res...
Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy, yet the freq...
CD28 and CTLA-4 are members of a family of Immunoglobulin-related receptors that are responsible for...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...
CTLA-4 and PD-1 are key immune checkpoint receptors that are targeted in the treatment of cancer. A ...
International audienceCD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal ...
Tumor cells are capable of limiting antitumor CD8+ T cell responses through their cell surface expre...
CD28, CTLA-4 and PD-L1, the three identified ligands for CD80/86, are pivotal positive and negative ...
Subsets of human tumors are infiltrated with tumor antigen-specific CD8+ T cells (TIL), yet despite ...
Costimulatory molecules function to stimulate or inhibit T cell activation. A balance between activa...
Immunotherapy is a promising approach for the treatment of primary and metastatic cancer because of ...
Tumor cells can inhibit immune responses against their survival by activating inhibitory immune chec...
Many cancers are termed immunoevasive due to expression of immunomodulatory ligands. Programmed deat...
Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early res...
Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy, yet the freq...
CD28 and CTLA-4 are members of a family of Immunoglobulin-related receptors that are responsible for...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
Summary: The PD-1 pathway, consisting of the co-inhibitory receptor PD-1 on T cells and its ligand (...
Immunotherapy targeting the Programmed Death (PD-1) receptor/ligand (L) "checkpoint" rapidly gains g...